157 results on '"Cannistra SA"'
Search Results
2. Characterization of adhesion molecules on human myeloma cell lines
Catalog
Books, media, physical & digital resources
3. Myeloid and erythroid progenitor cells from normal bone marrow adhere to collagen type I
4. Comparing Poly (ADP-Ribose) Polymerase Inhibitors With Standard Chemotherapy in BRCA-Mutated, Recurrent Ovarian Cancer: Lessons Learned From a Negative Trial.
5. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
6. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
7. Phase II trials in journal of clinical oncology.
8. Identification of functionally distinct domains of human granulocyte- macrophage colony-stimulating factor using monoclonal antibodies
9. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
10. Signal transduction of the human granulocyte-macrophage colony- stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins
11. Association between clonogenic cell growth and clinical risk group in B- cell chronic lymphocytic leukemia
12. Medical progress: cancer of the ovary.
13. Cancer of the uterine cervix.
14. Challenges and pitfalls of combining targeted agents in phase I studies.
15. Gynecologic oncology or medical oncology: what's in a name?
16. Intraperitoneal chemotherapy comes of age.
17. Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo
18. Differential expression of HLA-DR antigens in subsets of human CFU-GM
19. Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: direct analysis using partially purified colony- forming cells
20. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors
21. Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor- dependent mechanism
22. Performance of biopsies in clinical research.
23. Cancer of the ovary.
24. Flashback Foreword: Carboplatin Dosage Based on Renal Function.
25. Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?
26. The End of a Fantastic Voyage.
27. Challenges Faced by Medical Journals During the COVID-19 Pandemic.
28. Journal of Clinical Oncology's Data Sharing Policy for Clinical Trials.
29. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
30. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
31. Reply to R.J. Buckanovich et al.
32. Progress and Promise in Treating Gynecologic Cancers.
33. Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer.
34. When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?
35. Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?
36. Maintenance PARP inhibitor therapy: is maintaining quality of life enough?
37. In the Pursuit of Excellence: Reflections From the Editor-in-Chief of Journal of Clinical Oncology.
38. Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer.
39. Reply to C.M. Booth et al.
40. Evaluation of treatment benefit in Journal of Clinical Oncology.
41. Bevacizumab rechallenge after first line maintenance bevacizumab.
42. Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer.
43. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.
44. New initiatives at Journal of Clinical Oncology.
45. Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer.
46. Phase I studies of drug combinations.
47. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
48. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?
49. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer.
50. Gene-expression profiling in epithelial ovarian cancer.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.